{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37230983", "DateRevised": {"Year": "2023", "Month": "05", "Day": "29"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "26"}], "Language": ["eng"], "ELocationID": ["29", "10.1038/s41389-023-00475-1"], "Journal": {"ISSN": "2157-9024", "JournalIssue": {"Volume": "12", "Issue": "1", "PubDate": {"Year": "2023", "Month": "May", "Day": "26"}}, "Title": "Oncogenesis", "ISOAbbreviation": "Oncogenesis"}, "ArticleTitle": "CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer.", "Pagination": {"StartPage": "29", "MedlinePgn": "29"}, "Abstract": {"AbstractText": ["Immune-checkpoint (IC) modulators like the poliovirus receptor (PVR) and programmed death ligand 1 (PD-L1) attenuate innate and adaptive immune responses and are potential therapeutic targets for diverse malignancies, including triple-negative breast cancer (TNBC). The retinoblastoma tumor suppressor, pRB, controls cell growth through E2F1-3 transcription factors, and its inactivation drives metastatic cancer, yet its effect on IC modulators is contentious. Here, we show that RB-loss and high E2F1/E2F2 signatures correlate with expression of PVR, CD274 (PD-L1 gene) and other IC modulators and that pRB represses whereas RB depletion and E2F1 induce PVR and CD274 in TNBC cells. Accordingly, the CDK4/6 inhibitor, palbociclib, suppresses both PVR and PD-L1 expression. Palbociclib also counteracts the effect of CDK4 on SPOP, leading to its depletion, but the overall effect of palbociclib is a net reduction in PD-L1 level. Hydrochloric acid, commonly used to solubilize palbociclib, counteracts its effect and induces PD-L1 expression. Remarkably, lactic acid, a by-product of glycolysis, also induces PD-L1 as well as PVR. Our results suggest a model in which CDK4/6 regulates PD-L1 turnover by promoting its transcription via pRB-E2F1 and degradation via SPOP and that the CDK4/6-pRB-E2F pathway couples cell proliferation with the induction of multiple innate and adaptive immunomodulators, with direct implications for cancer progression, anti-CDK4/6- and IC-therapies."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": ["0009-0003-7880-7584"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada. m.shrestha@mail.utoronto.ca."}, {"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, Rm. 5R406, Toronto, Ontario, M5G 1L7, Canada. m.shrestha@mail.utoronto.ca."}], "LastName": "Shrestha", "ForeName": "Mariusz", "Initials": "M"}, {"Identifier": ["0000-0002-5434-287X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, Rm. 5R406, Toronto, Ontario, M5G 1L7, Canada."}], "LastName": "Wang", "ForeName": "Dong-Yu", "Initials": "DY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province and Chinese Academic of Sciences, 550014, Guiyang, Guizhou, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, 550025, Guiyang, China."}], "LastName": "Ben-David", "ForeName": "Yaacov", "Initials": "Y"}, {"Identifier": ["0000-0001-6104-6094"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada. eldad.zacksenhaus@utoronto.ca."}, {"Identifier": [], "Affiliation": "Toronto General Research Institute - University Health Network, 101 College Street, Max Bell Research Centre, Rm. 5R406, Toronto, Ontario, M5G 1L7, Canada. eldad.zacksenhaus@utoronto.ca."}], "LastName": "Zacksenhaus", "ForeName": "Eldad", "Initials": "E"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Oncogenesis", "NlmUniqueID": "101580004", "ISSNLinking": "2157-9024"}, "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352.", "ArticleIdList": ["PMC7116507", "29562194"]}, {"Citation": "Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313\u201326.", "ArticleIdList": ["PMC6538253", "30290139"]}, {"Citation": "Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254\u201367.", "ArticleIdList": ["PMC8790946", "35082367"]}, {"Citation": "Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386:2363\u201376.", "ArticleIdList": ["PMC9492301", "35660797"]}, {"Citation": "Narayan P, Wahby S, Gao JJ, Amiri-Kordestani L, Ibrahim A, Bloomquist E, et al. FDA approval summary: atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1. Clin Cancer Res. 2020;26:2284\u20139.", "ArticleIdList": ["32001481"]}, {"Citation": "Yamaguchi H, Wang SC, Hung MC. Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy. Clin Transl Med. 2022;12:e803.", "ArticleIdList": ["PMC9119611", "35588146"]}, {"Citation": "Miles D, Gligorov J, Andre F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32:994\u20131004.", "ArticleIdList": ["34219000"]}, {"Citation": "Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.", "ArticleIdList": ["PMC5013604", "27572267"]}, {"Citation": "Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216:982\u20131000.", "ArticleIdList": ["PMC6446862", "30872362"]}, {"Citation": "Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019;68:421\u201332.", "ArticleIdList": ["PMC6426808", "30564891"]}, {"Citation": "Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, et al. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol. 2018;52:379\u201388.", "ArticleIdList": ["PMC5741372", "29345283"]}, {"Citation": "Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352:227\u201331.", "ArticleIdList": ["PMC4940030", "26966191"]}, {"Citation": "Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di, et al. Regulation of PD-L1 expression by NF-kappaB in cancer. Front Immunol. 2020;11:584626.", "ArticleIdList": ["PMC7724774", "33324403"]}, {"Citation": "Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O, Jonjic S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol. 2019;16:40\u201352.", "ArticleIdList": ["PMC6318332", "30275538"]}, {"Citation": "Tsukerman P, Atieh A, Obeidat A, Paz K, Cinamon G, Rovis TL, et al. Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity. Cancer Immunol Res. 2022;10:P075."}, {"Citation": "Atieh A, Obiedat A, Cinamon G, Rovis TL, Brlic PK, Hirsl L, et al. 254 NTX-1088, a potent anti-PVR Mab induces DNAM1-mediated antitumor immunity. J Immunother Cancer. 2021;9:A275."}, {"Citation": "Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer. 2022;10:e004711.", "ArticleIdList": ["PMC8981293", "35379739"]}, {"Citation": "Sullivan DP, Seidman MA, Muller WA. Poliovirus receptor (CD155) regulates a step in transendothelial migration between PECAM and CD99. Am J Pathol. 2013;182:1031\u201342.", "ArticleIdList": ["PMC3586692", "23333754"]}, {"Citation": "Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol. 2008;9:603\u201315.", "ArticleIdList": ["18648374"]}, {"Citation": "Zhuo B, Li Y, Gu F, Li Z, Sun Q, Shi Y, et al. Overexpression of CD155 relates to metastasis and invasion in osteosarcoma. Oncol Lett. 2018;15:7312\u20138.", "ArticleIdList": ["PMC5920504", "29725446"]}, {"Citation": "Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61\u201370.", "ArticleIdList": ["PMC3465532", "23000897"]}, {"Citation": "Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297\u2013303.", "ArticleIdList": ["PMC5995337", "28783718"]}, {"Citation": "Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. J Clin Invest. 2016;126:3739\u201357.", "ArticleIdList": ["PMC5096803", "27571409"]}, {"Citation": "Cuitino MC, Pecot T, Sun D, Kladney R, Okano-Uchida T, Shinde N, et al. Two distinct E2F transcriptional modules drive cell cycles and differentiation. Cell Rep. 2019;27:3547\u201360.e3545.", "ArticleIdList": ["PMC6673649", "31130414"]}, {"Citation": "Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022;375:eabc1495.", "ArticleIdList": ["PMC9048628", "35025636"]}, {"Citation": "Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339.", "ArticleIdList": ["26947331"]}, {"Citation": "Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348.", "ArticleIdList": ["27717303"]}, {"Citation": "Jin X, Ding D, Yan Y, Li H, Wang B, Ma L, et al. Phosphorylated RB promotes cancer immunity by inhibiting NF-kappaB activation and PD-L1 expression. Mol Cell. 2019;73:22\u201335.e26.", "ArticleIdList": ["PMC8968458", "30527665"]}, {"Citation": "Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91\u20135.", "ArticleIdList": ["PMC5754234", "29160310"]}, {"Citation": "Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma. Clin Cancer Res. 2019;25:6511\u201323.", "ArticleIdList": ["31375512"]}, {"Citation": "Wellenstein MD, de Visser KE. Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 2018;48:399\u2013416.", "ArticleIdList": ["29562192"]}, {"Citation": "Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010;107:6994\u20139.", "ArticleIdList": ["PMC2872436", "20335537"]}, {"Citation": "Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, et al. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci USA. 2009;106:16387\u201392.", "ArticleIdList": ["PMC2752567", "19805309"]}, {"Citation": "Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Sci Rep. 2019;9:19107.", "ArticleIdList": ["PMC6911070", "31836816"]}, {"Citation": "Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, et al. NF-kappaB gene signature predicts prostate cancer progression. Cancer Res. 2014;74:2763\u201372.", "ArticleIdList": ["PMC4024337", "24686169"]}, {"Citation": "Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, et al. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633\u20137.", "ArticleIdList": ["28344319"]}, {"Citation": "Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018;9:1908.", "ArticleIdList": ["PMC5954021", "29765039"]}, {"Citation": "Dang F, Nie L, Zhou J, Shimizu K, Chu C, Wu Z, et al. Inhibition of CK1epsilon potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer. Nat Commun. 2021;12:5386.", "ArticleIdList": ["PMC8433397", "34508104"]}, {"Citation": "Watson MJ, Delgoffe GM. Fighting in a wasteland: deleterious metabolites and antitumor immunity. J Clin Invest. 2022;132:e148549.", "ArticleIdList": ["PMC8759785", "35040434"]}, {"Citation": "Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 2003;424:223\u20138.", "ArticleIdList": ["12853964"]}, {"Citation": "Kitajima S, Yoshida A, Kohno S, Li F, Suzuki S, Nagatani N, et al. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene. 2017;36:5145\u201357.", "ArticleIdList": ["28481867"]}, {"Citation": "Zacksenhaus E, Shrestha M, Liu JC, Vorobieva I, Chung PED, Ju Y, et al. Mitochondrial OXPHOS induced by RB1 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer. 2017;3:768\u201379.", "ArticleIdList": ["29120753"]}, {"Citation": "Zacksenhaus E, Egan SE. Progression to metastasis of solid cancer. Cancers. 2021;13:717.", "ArticleIdList": ["PMC7916396", "33578666"]}, {"Citation": "Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L, et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of I\u03baB\u03b1. Cell Metab. 2022;34:1312\u201324.e1316.", "ArticleIdList": ["36007522"]}, {"Citation": "Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471\u20135.", "ArticleIdList": ["PMC5570667", "28813415"]}, {"Citation": "Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22:2978\u201394.", "ArticleIdList": ["29539425"]}, {"Citation": "Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216\u201333.", "ArticleIdList": ["PMC5809273", "29101163"]}, {"Citation": "Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175:984\u201397.e924.", "ArticleIdList": ["PMC6410377", "30388455"]}, {"Citation": "Liu JC, Granieri L, Shrestha M, Wang DY, Vorobieva I, Rubie EA, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep. 2018;23:112\u201326.", "ArticleIdList": ["PMC9357459", "29617654"]}, {"Citation": "Gong X, Du J, Parsons SH, Merzoug FF, Webster Y, Iversen PW, et al. Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discov. 2019;9:248\u201363.", "ArticleIdList": ["30373917"]}, {"Citation": "Dhawan A, Scott JG, Harris AL, Buffa FM. Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors. Nat Commun. 2018;9:5228.", "ArticleIdList": ["PMC6286392", "30531873"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "1", "Day": "2"}, {"Year": "2023", "Month": "5", "Day": "4"}, {"Year": "2023", "Month": "5", "Day": "2"}, {"Year": "2023", "Month": "5", "Day": "26", "Hour": "1", "Minute": "6"}, {"Year": "2023", "Month": "5", "Day": "26", "Hour": "1", "Minute": "5"}, {"Year": "2023", "Month": "5", "Day": "25", "Hour": "23", "Minute": "15"}, {"Year": "2023", "Month": "5", "Day": "26"}], "PublicationStatus": "epublish", "ArticleIdList": ["37230983", "PMC10213015", "10.1038/s41389-023-00475-1", "10.1038/s41389-023-00475-1"]}}], "PubmedBookArticle": []}